Deoxynojirimycin - CAS 19130-96-2
Catalog number: B0084-061939
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C6H13NO4
Molecular Weight:
163.17
COA:
Inquire
Targets:
α- and β-glucosidases
Description:
Deoxynojirimycin inhibits mammalian glucosidase 1. As well, it inhibits intestinal and lysosmal alpha-glucosidases, beta-glucosidase from sweet almonds, pancreatic alpha-amylase and amyloglucosidase.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-061939 250 mg $198 In stock
B0084-061939 1 g $598 In stock
Bulk Inquiry
Purity:
0.98
Appearance:
White to Off-White Solid
Synonyms:
(2R,3R,4R,5S)-2-(Hydroxymethyl)-3,4,5-piperidinetriol; 5-Amino-1,5-dideoxy-D-glucopyranose; Duvoglustat; Moranolin; Moranoline; DNJ
MSDS:
Inquire
InChIKey:
LXBIFEVIBLOUGU-JGWLITMVSA-N
InChI:
InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1
Canonical SMILES:
C1C(C(C(C(N1)CO)O)O)O
1. Atomic resolution analyses of the binding of xylobiose-derived deoxynojirimycin and isofagomine to xylanase Xyn10A
Tracey M. Gloster, Spencer J. Williams, Gideon J. Davies*. Chem. Commun., 2004, 1794–1795
The protonation state of imino-sugar glycosidase inhibitors and that of the catalytic centre to which they bind are central to their action. Imino-sugars such as 1-deoxynojrimycin (1) and isofagomine (2) are widely studied glycosidase inhibitors and it is commonly assumed that these inhibitors interact with the catalytic apparatus in a manner that has been interpreted either as mimicking the oxocarbenium ion-like transition state or simply being adventitious. Whilst the former explanation seems intuitively reasonable, more quantitative analyses, such as the absence of a correlation between kcat/KM and 1/Ki for a series of modified substrates and inhibitors, favour the latter interpretation. Regardless, most work assumes that these compounds bind in their protonated forms, but this has only recently been demonstrated through crystallography at “atomic resolution” with a cellobiose-derived form of 2.Here we present the “atomic resolution” structures of the Streptomyces lividans xylanase Xyn10A in complex with xylobiose-derived deoxynojirimycin (3) and isofagomine (4) at both pH 5.8 and 7.5.
2. Targeted drugs by olefin metathesis: piperidine-based iminosugars
Ileana Dragutan,* Valerian Dragutan and Albert Demonceau. RSC Adv., 2012, 2, 719–736
Of the piperidine-based azasugars class (Scheme 1), two members, N-butyl-1-deoxynojirimycin (Miglustat, 11)and N-hydroxyethyl-1-deoxynojirimycin (Miglitol, 12; FDA approved), have presently reached the market as drugs against, respectively, Gaucher’s disease (the most common glycosphingolipid lysosomal storage disorder) and type II diabetes (diabetes mellitus). The primary pharmacological activity of Miglustat is inhibition of the enzyme glucosylceramide synthase, catalyzing the first step in the biosynthesis of glycosphingolipids, i.e. the formation of glucosylceramide. Therefore, the treatment of Gaucher’s disease with Miglustat is based on the concept of substrate reduction therapy. In the body Miglustat exhibits a large volume of distribution having the capacity to access organs located deep within, however, itmay only be used in the treatment of type 1 Gaucher patients for whom enzyme replacement therapy is unsuitable. Early studies have shown Miglustat to be also active against the HIV infection. The second commercial drug,Miglitol, is an oral antidiabetic drug which acts by inhibiting alpha-glucosidases (glycoside hydrolysis enzymes), and consequently the ability of the body to breakdown complex carbohydrates into glucose.
3. Glycosidase inhibition by novel guanidinium and urea iminosugar derivatives
Raymond Kooij, Hilbert M. Branderhorst, Simon Bonte, Sara Wieclawska, Nathaniel I. Martin* and Roland J. Pieters*. Med. Chem. Commun., 2013, 4, 387–393
The potent and selective inhibition of glycosidases is an important goal for the development of therapeutics. Glycosidases cleave the glycosidic bonds in oligosaccharides and glycoconjugates. Blocking glycosidase activity can aid in the treatment of diabetes, viral infections, lysosomal storage diseases, and cancer. Iminosugars have been shown to be highly effective inhibitors but their limited selectivity can lead to side effects when applied therapeutically. It is clear that improving the selectivity of iminosugars as glycosidase inhibitors is an important goal. The effectiveness of iminosugars as glycosidase inhibitors in many cases depends on their ability to mimic the relevant transition state in the cleavage process. Considering the vast rate enhancements of glycosidases, these enzymes bind the transition state with very high affinity. Consequently, a transition state mimic has the potential to be a very strong inhibitor. The mimicry depends on the complementarity with respect to charge and shape. These issues are intimately linked to the hybridization state of the ‘anomeric carbon’ and the endocyclic oxygen or in the case of derivatives of deoxynojirimycin 1 (Fig. 1) the nitrogen. These atoms should have a considerable sp2 character. We here focused on the hybridization aspect by straightforward derivatisation of the nitrogen of deoxynojirimycin 1 to explore new structural motifs for glycosidase inhibition.
4. Total syntheses of D-allo-1-deoxynojirimycin and L-talo-1-deoxynojirimycin via reductive cyclization
Subhash P. Chavan,* Nilesh B. Dumare and Kailash P. Pawar. RSC Adv.,2014, 4,40852–40858
Azasugars or iminosugars have significant biological activities and they act as glycosidase inhibitors and are extensively used for the treatment of AIDS, cancer, diabetes and viral infections. The configuration of hydroxyl groups on the piperidine ring has been shown to have different and profound biological activities. Recently, derivatives of 1-deoxynojirimycin (1-DNJ) 1 such as miglitol 2 (ref. 2) and N-butyl-1-deoxynojirimycin 3 (ref. 2) (Fig. 1) have also attracted great deal of attention due to their promising biological activities. Miglitol 2 is approved for non-insulin dependent diabetes treatment and N-butyl-1-deoxynojirimycin 3 for Gauchers disease. However, very less attention has been paid towards the syntheses of other isomers of 1-DNJ 1 such as L-talo-1-deoxynojirimycin (L-talo-1-DNJ) and D-allo-1-deoxynojirimycin (D-allo-1-DNJ).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related α- and β-glucosidases Products


CAS 210110-90-0 Miglustat HCl

Miglustat HCl
(CAS: 210110-90-0)

Miglustat HCl is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1). It also inhibits glucosidase I and II, as well as H...

CAS 73285-50-4 1-Deoxynojirimycin hydrochloride

1-Deoxynojirimycin hydrochloride
(CAS: 73285-50-4)

1-Deoxynojirimycin, also called Duvoglustat, is produced by Bacillus species. It is a glucose analog that can inhibit α-glucosidase I and II. 1-Deoxynojirimycin...

CAS 79831-76-8 Castanospermine

Castanospermine
(CAS: 79831-76-8)

Castanospermine is an inhibitor of all forms of α- and β-glucosidases, especially glucosidase l. It inhibits lysosomal and neutral α-glucosidases with Ki values...

CAS 19130-96-2 Deoxynojirimycin

Deoxynojirimycin
(CAS: 19130-96-2)

Deoxynojirimycin inhibits mammalian glucosidase 1. As well, it inhibits intestinal and lysosmal alpha-glucosidases, beta-glucosidase from sweet almonds, pancrea...

Chemical Structure

CAS 19130-96-2 Deoxynojirimycin

Quick Inquiry

Verification code

Featured Items